Bactolife™ receives USD 5 million in new funding to address gastrointestinal infections worldwide – Bactolife
Summary
Our shared concern for global access to effective treatments for prevalent infectious diseases makes the Bill & Melinda Gates Foundation an ideal organization to collaborate with, and we are excited for the potential impact this work will have in addressing pressing global health challenges.Globally, there are more than 1.6 billion cases of diarrheal diseases annually, which at best means stomach upsets. Annual health care costs are increasing, and there are limited options to avoid disease manifestation in the first place. With Bactolifes technology platform and the investment made by the Bill & Melinda Gates Foundation, Binding Proteins can be formulated into food and feed products, making them easy to ingest.Bactolife is a growing company in the field of gut microbiome health in the food and feed industry. Its proprietary platform consists of a technology for selecting and producing Binding Proteins without targeting growth or killing the bacteria directly. Binding Proteins are stable and highly cost-effective and can be produced at a large scale using leading-edge systems for biomanufacturing.Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.